Chronic lymphocytic leukemia (CLL) is a type of leukemia—a cancer of the bone marrow and blood.
Better Survival Rates for CLL
Studies have shown that the first treatment you receive for cancer is by far the most important. On average, leukemia patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere. Our patients diagnosed with CLL receive expertly targeted, comprehensive care from a team of specialists who focus almost exclusively on treating this disease.
Access to Clinical Studies
SCCA, with its founding organizations Fred Hutch and UW Medicine, is a world leader in leukemia research and was formed, in part, to bring promising new treatments to patients faster. For people with CLL, this means more treatment options than you might find elsewhere, including the chance to participate in a clinical study for CLL.
Our researchers pioneered one of the most effective leukemia treatments, bone marrow transplantation, more than 50 years ago and continue to refine it today—for example, developing transplant options for people who have not found a matched donor. We are also advancing other key leukemia treatments, including improved chemotherapy and targeted therapies. For example, SCCA researchers were principal investigators on clinical studies that led to the approval in 2014 of a new targeted therapy known as idelalisib (Zydelig).
Excellent Transplant Results
Depending on the specifics of your leukemia, you may have several treatment options. One option—a blood or bone marrow transplant—has transformed some leukemias and related cancers, once thought incurable, into highly treatable diseases with survival rates as high as 80 percent. If your condition requires a bone marrow transplant, you should know that the Fred Hutch Bone Marrow Transplant Program at SCCA is one of 15 centers whose patients achieved higher-than-expected survival rates, according to a recent multi-year study by the Center for International Blood and Marrow Transplant Research (CIBMTR). We’ve performed more bone marrow transplants than any other institution in the world.